Observations by NASA’s SPHEREx (Spectro-Photometer for the History of the Universe, Epoch of Reionization and Ices Explorer) show the infrared light emitted by the dust, water, organic molecules, and carbon dioxide contained within comet 3I/ATLAS’s coma.
It's aimed at strengthening transparency and human-led reporting in an era increasingly crowded by AI.The post Journalists become the story in News Corp Australia’s ‘We’re for You’ campaign appeared first on Mediaweek.
NASA's SPHEREx Mission Spots 3I/ATLAS's Bright Envelope Universe TodayNASA’s SPHEREx Mission Tracks Brightening of Interstellar Comet NASA Science (.gov)Building blocks of life detected on 3I/ATLAS — scientists say it could be an interstellar ‘gardener’ seeding the cosmos New York PostNASA space telescope sees interstellar visitor comet 3I/ATLAS flare up while exiting the solar system SpaceKorea, NASA's SPHEREx Finds Life's Building Blocks in 3I/ATLAS 조선일보
Nancy Guthrie, the 84-year-old mother of "Today" show host Savannah Guthrie, has been missing for over a week.
The NewsHoward Lutnick’s Jeffrey Epstein problem may be getting worse.Republicans on Capitol Hill are getting more unsettled about revelations that the Commerce Secretary’s ties to Epstein were closer than he acknowledged. And Trump administration allies are now actively debating his fate — even...
The head of the U.S. Federal Aviation Administration said on Tuesday he expected Canada would announce it was certifying some Gulfstream business jets that had been delayed for years, resolving an issue highlighted by President Donald Trump.“I think we’ve resolved the issues with Canada,” FAA...
Nearly 90,000 tech support tickets handled; 52,697 vendor invoices processed; 4,559 PCs freshly configured; and four pay cycles processed for more than...
Artificial intelligence is rapidly transforming America's job market, displacing white-collar workers while creating new technical roles, yet the nation lacks a comprehensive plan for workforce retraining, social safety nets, and equitable distribution of AI-driven economic gains.
Swatch must revitalize its innovation consolidate its brand lineup and undergo governance reforms to counteract years of decreasing profits and regain investor trust The Swiss watch giant proposed the appointment of businessman Andreas Rickenbacher to its board marking only the second new board addition in a decade
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies.- In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for 7 days. ASC36 tablets also reduced food intake significantly. - In a head-to-head diet-induced obese (DIO) rat model, ASC36 demonstrated approximately 32% and 91% greater relative body weight reduction compared to eloralintide and petrelintide, respectively. - ASC36 oral tablets are expected to utilize a lower dose due to potentially better oral bioavailability and efficacy. This superior weight loss per milligram of ASC36 peptide may also provide scalability advantages in manufacturing.- Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC36 oral tablets is expected in the second quarter of 2026.HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC36 oral tablets, its first oral amylin receptor peptide agonist, for clinical development. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC36 oral tablets for the treatment of obesity in the second quarter of 2026.ASC36 oral tablets were developed with Ascletis' proprietary Peptide Oral Transport ENhancement Technology (POTENT). In non-human primates (NHPs), 10 mg ASC36 oral tablet per animal dosed once daily for 7 days achieved absolute oral bioavailability[1] of 8% and elimination half-life of 116 hours at steady state; 25 mg ASC36 oral tablet per animal dosed once daily for 7 days achieved absolute oral bioavailability of 6% and elimination half-life of 167 hours at steady state. The long elimination half-life (116 hours to 167 hours) of ASC36 oral tablets supports once-daily and less frequent oral dosing.ASC36 oral tablets demonstrated significant weight loss in both NHP and diet-induced obese (DIO) rat models. In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for 7 days. ASC36 tablets also reduced food intake significantly.In a head-to-head DIO rat model, after 7 days of treatment, ASC36 demonstrated approximately 32% and 91% greater relative body weight reduction compared to eloralintide and petrelintide, respectively. ASC36 oral tablets are expected to utilize a lower dose, relative to a recently FDA approved oral GLP-1R peptide agonist, due to potentially better oral bioavailability and efficacy. This superior weight loss per milligram of ASC36 peptide may also provide scalability advantages in manufacturing.ASC36, an amylin receptor peptide agonist, was discovered and developed in-house utilizing Ascletis' Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD). ASC36 oral tablet formulation was developed and optimized by Ascletis' POTENT technology for delivery of oral peptides."ASC36 oral tablets is an important amylin agonist among three key amylin drug candidates, i.e. an oral small molecule amylin, an oral peptide amylin and a once-monthly subcutaneous injectable peptide amylin," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. "Leveraging our three proprietary technology platforms, including AISBDD, Ultra-Long-Acting Platform (ULAP) and POTENT, Ascletis has successfully established a highly competitive, differentiated and diverse pipeline portfolio which can potentially effectively address the various treatment needs of patients with obesity and other metabolic diseases."[1] Absolute oral bioavailability: the percentage of an orally administered drug that reaches the systemic circulation (bloodstream), compared to an intravenous (IV) dose of the same drugAbout Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).For more information, please visit www.ascletis.com.Contact:Peter VozzoICR Healthcare443-231-0505 (U.S.)Peter.vozzo@icrhealthcare.com Ascletis Pharma Inc. PR and IR teams+86-181-0650-9129 (China)pr@ascletis.comir@ascletis.com
WhatsApp Business could potentially start charging users who want to link more than four devices to the same account in a future update.
A bug in Google Messages is causing severe battery drain and overheating on some devices. Here's a temporary fix while you wait for Google to push an update.
Redmi 10 Power Price in India: Redmi has launched its new smartphone Redmi 10 Power in India. The smartphone was launched along with Redmi 10A, on Wednesday, 20 April in India
The premium Alienware m15 R7 and m17 R5 highlight four new Ryzen-powered systems.
Apple is offering its new firmware update for the MagSafe accessory that promises to give you faster charging for the compatible iPhone models.
System apps with native call-recording functionality remain unaffected.
The OnePlus Nord 2T India launch may take place soon as the moniker has been spotted on the TDRA certification. The OnePlus Nord 2T's camera details have also been leaked. Here are the expected specifications of the device.
The iPhone 16 is likely to be the first Apple device to skip the camera notch.
Garena Free Fire Max redeem codes are 12-digit codes that are region-specific and can be used by players to gain an edge over rivals in every round of the battle royale game.
We are still not sure that no-charger policy will be limited to Narzo 50A Prime or it will be extended to other Realme budget, mid-segment and premium phones
